Andrew Melie has a wealth of experience in the analytical chemistry field. Andrew began their career in 2011 as a Biological Science Technician at the University of Nebraska-Lincoln, where they reported on research, data collection, and tasks completed by all members of the program. Andrew then moved on to Seachem Laboratories Inc. in 2014, where they held the positions of Lead Research Scientist and Assistant Research and Development Director. In 2018, Andrew became a Senior Chemist at HUVEPHARMA, INC. where they developed and updated methods, SOPs, and assays to support pharmaceutical quality testing. In 2020, they joined Editas Medicine as a Senior Research Associate where they designed, qualified, and validated methods for analytical characterization of oligonucleotides and their raw materials. Most recently, Andrew began working as an Analytical Scientist at Perfuse Therapeutics in 2022, where they support drug substance and drug product analytical chemistry activities in their advancement through preclinical and clinical stage development.
Andrew Melie earned their Bachelor of Science in Zoology/Animal Biology from Michigan State University in 2008. Andrew then went on to receive their Master's degree in Biological Sciences from the University of Nebraska-Lincoln in 2013.
February, 2022 - present
AI Scientist at Ekkel AI
Chief Scientific Officer at Jubilant Radiopharma
Director, Research And Strategic Initiatives at American Association for State and Local History (AASLH)
Data Science Vice President at PS AI Labs
Co-founder & CEO At 369 Labs | Beat Energy at Embertec